APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Anti-Obesity Drugs (Anti-obesity Medication)

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Anti-Obesity Drugs (Anti-obesity Medication) Market Analysis and Forecast 2026-2032

21 December 2025206 pages

Choose your research edition.

Industry ResearchAnti-Obesity Drugs (Anti-obesity Medication) Industry Research Report 2026150 pages · $2,950 USDIndustry Growth & TrendsGlobal Anti-Obesity Drugs (Anti-obesity Medication) Industry Growth and Trends Forecast to 2032126 pages · $3,450 USDMarket StructureGlobal Anti-Obesity Drugs (Anti-obesity Medication) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anti-Obesity Drugs (Anti-obesity Medication) Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Anti-Obesity Drugs (Anti-obesity Medication) Market Analysis and Forecast 2026-2032206 pages · $4,950 USD

Market perspective

The global Anti-Obesity Drugs (Anti-obesity Medication) market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Anti-Obesity Drugs (Anti-obesity Medication) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Anti-Obesity Drugs (Anti-obesity Medication) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Anti-Obesity Drugs (Anti-obesity Medication) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Anti-Obesity Drugs (Anti-obesity Medication) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Anti-Obesity Drugs (Anti-obesity Medication) include Eisai, Sanofi, Novo Nordisk, Merck, F.Hoffmann-La Roche, Pfizer, GlaxoSmithKline, Bayer AG and AstraZeneca, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Anti-Obesity Drugs (Anti-obesity Medication), sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Anti-Obesity Drugs (Anti-obesity Medication), also provides the sales of main regions and countries. Of the upcoming market potential for Anti-Obesity Drugs (Anti-obesity Medication), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Anti-Obesity Drugs (Anti-obesity Medication) sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Anti-Obesity Drugs (Anti-obesity Medication) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Anti-Obesity Drugs (Anti-obesity Medication) sales, projected growth trends, production technology, application and end-user industry.

Anti-Obesity Drugs (Anti-obesity Medication) Segment by Company

Eisai

Sanofi

Novo Nordisk

Merck

F.Hoffmann-La Roche

Pfizer

GlaxoSmithKline

Bayer AG

AstraZeneca

Zafgan

Vivus

Shionogi

Rhythm Pharmaceuticals

Orexigen Therapeutics

Norgine

Boehringer Ingelheim

Arena Pharmaceuticals

Amylin

Alizyme

Alizyme

Anti-Obesity Drugs (Anti-obesity Medication) Segment by Type

Rx Drug

OTC Drug

Anti-Obesity Drugs (Anti-obesity Medication) Segment by Application

Middle Aged (41-60)

Juvenile (7-17)

Youth (18-40)

Elderly (Above 60)

Childhood (0-6)

Anti-Obesity Drugs (Anti-obesity Medication) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-Obesity Drugs (Anti-obesity Medication) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anti-Obesity Drugs (Anti-obesity Medication) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-Obesity Drugs (Anti-obesity Medication).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Anti-Obesity Drugs (Anti-obesity Medication) in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Anti-Obesity Drugs (Anti-obesity Medication) manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Anti-Obesity Drugs (Anti-obesity Medication) sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Rx Drug Major Manufacturers Table 3. OTC Drug Major Manufacturers Table 4. Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Middle Aged (41-60) Major Manufacturers Table 6. Juvenile (7-17) Major Manufacturers Table 7. Youth (18-40) Major Manufacturers Table 8. Elderly (Above 60) Major Manufacturers Table 9. Childhood (0-6) Major Manufacturers Table 10. Anti-Obesity Drugs (Anti-obesity Medication) Industry Trends Table 11. Anti-Obesity Drugs (Anti-obesity Medication) Industry Drivers Table 12. Anti-Obesity Drugs (Anti-obesity Medication) Industry Opportunities and Challenges Table 13. Anti-Obesity Drugs (Anti-obesity Medication) Industry Restraints Table 14. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 15. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Region (2021-2026) & (US$ Million) Table 16. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Region (2027-2032) & (US$ Million) Table 17. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Region (2021-2026) Table 18. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Region (2027-2032) Table 19. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k units) Table 20. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Region (2021-2026) & (k units) Table 21. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Region (2027-2032) & (k units) Table 22. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Region (2021-2026) Table 23. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Region (2027-2032) Table 24. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Manufacturers (2021-2026) Table 26. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Manufacturers (2021-2026) Table 28. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Price (US$/unit) of Manufacturers (2021-2026) Table 29. Global Anti-Obesity Drugs (Anti-obesity Medication) Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 30. Global Anti-Obesity Drugs (Anti-obesity Medication) Key Manufacturers Manufacturing Sites & Headquarters Table 31. Global Anti-Obesity Drugs (Anti-obesity Medication) Manufacturers, Product Type & Application Table 32. Global Anti-Obesity Drugs (Anti-obesity Medication) Manufacturers' Establishment Date Table 33. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 34. Global Anti-Obesity Drugs (Anti-obesity Medication) by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 35. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type (2021-2026) & (US$ Million) Table 37. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type (2027-2032) & (US$ Million) Table 38. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Type (2021-2026) Table 39. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Type (2027-2032) Table 40. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type 2021 VS 2025 VS 2032 (k units) Table 41. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2021-2026) & (k units) Table 42. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2027-2032) & (k units) Table 43. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Type (2021-2026) Table 44. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Type (2027-2032) Table 45. Global Anti-Obesity Drugs (Anti-obesity Medication) Price by Type (2021-2026) & (US$/unit) Table 46. Global Anti-Obesity Drugs (Anti-obesity Medication) Price by Type (2027-2032) & (US$/unit) Table 47. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Application (2021-2026) & (US$ Million) Table 49. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Application (2027-2032) & (US$ Million) Table 50. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Application (2021-2026) Table 51. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Application (2027-2032) Table 52. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application 2021 VS 2025 VS 2032 (k units) Table 53. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2021-2026) & (k units) Table 54. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2027-2032) & (k units) Table 55. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Application (2021-2026) Table 56. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Application (2027-2032) Table 57. Global Anti-Obesity Drugs (Anti-obesity Medication) Price by Application (2021-2026) & (US$/unit) Table 58. Global Anti-Obesity Drugs (Anti-obesity Medication) Price by Application (2027-2032) & (US$/unit) Table 59. Eisai Company Information Table 60. Eisai Business Overview Table 61. Eisai Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 62. Eisai Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 63. Eisai Recent Development Table 64. Sanofi Company Information Table 65. Sanofi Business Overview Table 66. Sanofi Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 67. Sanofi Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 68. Sanofi Recent Development Table 69. Novo Nordisk Company Information Table 70. Novo Nordisk Business Overview Table 71. Novo Nordisk Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 72. Novo Nordisk Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 73. Novo Nordisk Recent Development Table 74. Merck Company Information Table 75. Merck Business Overview Table 76. Merck Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 77. Merck Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 78. Merck Recent Development Table 79. F.Hoffmann-La Roche Company Information Table 80. F.Hoffmann-La Roche Business Overview Table 81. F.Hoffmann-La Roche Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 82. F.Hoffmann-La Roche Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 83. F.Hoffmann-La Roche Recent Development Table 84. Pfizer Company Information Table 85. Pfizer Business Overview Table 86. Pfizer Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. Pfizer Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 88. Pfizer Recent Development Table 89. GlaxoSmithKline Company Information Table 90. GlaxoSmithKline Business Overview Table 91. GlaxoSmithKline Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. GlaxoSmithKline Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 93. GlaxoSmithKline Recent Development Table 94. Bayer AG Company Information Table 95. Bayer AG Business Overview Table 96. Bayer AG Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. Bayer AG Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 98. Bayer AG Recent Development Table 99. AstraZeneca Company Information Table 100. AstraZeneca Business Overview Table 101. AstraZeneca Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. AstraZeneca Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 103. AstraZeneca Recent Development Table 104. Zafgan Company Information Table 105. Zafgan Business Overview Table 106. Zafgan Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. Zafgan Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 108. Zafgan Recent Development Table 109. Vivus Company Information Table 110. Vivus Business Overview Table 111. Vivus Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 112. Vivus Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 113. Vivus Recent Development Table 114. Shionogi Company Information Table 115. Shionogi Business Overview Table 116. Shionogi Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 117. Shionogi Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 118. Shionogi Recent Development Table 119. Rhythm Pharmaceuticals Company Information Table 120. Rhythm Pharmaceuticals Business Overview Table 121. Rhythm Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 122. Rhythm Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 123. Rhythm Pharmaceuticals Recent Development Table 124. Orexigen Therapeutics Company Information Table 125. Orexigen Therapeutics Business Overview Table 126. Orexigen Therapeutics Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 127. Orexigen Therapeutics Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 128. Orexigen Therapeutics Recent Development Table 129. Norgine Company Information Table 130. Norgine Business Overview Table 131. Norgine Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 132. Norgine Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 133. Norgine Recent Development Table 134. Boehringer Ingelheim Company Information Table 135. Boehringer Ingelheim Business Overview Table 136. Boehringer Ingelheim Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 137. Boehringer Ingelheim Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 138. Boehringer Ingelheim Recent Development Table 139. Arena Pharmaceuticals Company Information Table 140. Arena Pharmaceuticals Business Overview Table 141. Arena Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 142. Arena Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 143. Arena Pharmaceuticals Recent Development Table 144. Amylin Company Information Table 145. Amylin Business Overview Table 146. Amylin Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 147. Amylin Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 148. Amylin Recent Development Table 149. Alizyme Company Information Table 150. Alizyme Business Overview Table 151. Alizyme Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 152. Alizyme Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 153. Alizyme Recent Development Table 154. Alizyme Company Information Table 155. Alizyme Business Overview Table 156. Alizyme Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 157. Alizyme Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 158. Alizyme Recent Development Table 159. North America Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type (2021-2026) & (US$ Million) Table 160. North America Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type (2027-2032) & (US$ Million) Table 161. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2021-2026) & (k units) Table 162. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2027-2032) & (k units) Table 163. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales Price by Type (2021-2026) & (US$/unit) Table 164. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales Price by Type (2027-2032) & (US$/unit) Table 165. North America Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Application (2021-2026) & (US$ Million) Table 166. North America Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Application (2027-2032) & (US$ Million) Table 167. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2021-2026) & (k units) Table 168. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2027-2032) & (k units) Table 169. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales Price by Application (2021-2026) & (US$/unit) Table 170. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales Price by Application (2027-2032) & (US$/unit) Table 171. North America Anti-Obesity Drugs (Anti-obesity Medication) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 172. North America Anti-Obesity Drugs (Anti-obesity Medication) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 173. North America Anti-Obesity Drugs (Anti-obesity Medication) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 174. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 175. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2021-2026) & (k units) Table 176. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2027-2032) & (k units) Table 177. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales Price by Country (2021-2026) & (US$/unit) Table 178. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales Price by Country (2027-2032) & (US$/unit) Table 179. United States Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2021-2032) & (US$ Million) Table 180. Canada Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2021-2032) & (US$ Million) Table 181. Mexico Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2021-2032) & (US$ Million) Table 182. Europe Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type (2021-2026) & (US$ Million) Table 183. Europe Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type (2027-2032) & (US$ Million) Table 184. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2021-2026) & (k units) Table 185. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2027-2032) & (k units) Table 186. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales Price by Type (2021-2026) & (US$/unit) Table 187. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales Price by Type (2027-2032) & (US$/unit) Table 188. Europe Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Application (2021-2026) & (US$ Million) Table 189. Europe Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Application (2027-2032) & (US$ Million) Table 190. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2021-2026) & (k units) Table 191. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2027-2032) & (k units) Table 192. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales Price by Application (2021-2026) & (US$/unit) Table 193. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales Price by Application (2027-2032) & (US$/unit) Table 194. Europe Anti-Obesity Drugs (Anti-obesity Medication) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 195. Europe Anti-Obesity Drugs (Anti-obesity Medication) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 196. Europe Anti-Obesity Drugs (Anti-obesity Medication) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 197. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 198. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2021-2026) & (k units) Table 199. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2027-2032) & (k units) Table 200. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales Price by Country (2021-2026) & (US$/unit) Table 201. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales Price by Country (2027-2032) & (US$/unit) Table 202. Germany Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2021-2032) & (US$ Million) Table 203. France Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2021-2032) & (US$ Million) Table 204. U.K. Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2021-2032) & (US$ Million) Table 205. Italy Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2021-2032) & (US$ Million) Table 206. Russia Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2021-2032) & (US$ Million) Table 207. Spain Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2021-2032) & (US$ Million) Table 208. Netherlands Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2021-2032) & (US$ Million) Table 209. Switzerland Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2021-2032) & (US$ Million) Table 210. Sweden Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2021-2032) & (US$ Million) Table 211. Poland Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2021-2032) & (US$ Million) Table 212. China Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type (2021-2026) & (US$ Million) Table 213. China Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type (2027-2032) & (US$ Million) Table 214. China Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2021-2026) & (k units) Table 215. China Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2027-2032) & (k units) Table 216. China Anti-Obesity Drugs (Anti-obesity Medication) Sales Price by Type (2021-2026) & (US$/unit) Table 217. China Anti-Obesity Drugs (Anti-obesity Medication) Sales Price by Type (2027-2032) & (US$/unit) Table 218. China Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Application (2021-2026) & (US$ Million) Table 219. China Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Application (2027-2032) & (US$ Million) Table 220. China Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2021-2026) & (k units) Table 221. China Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2027-2032) & (k units) Table 222. China Anti-Obesity Drugs (Anti-obesity Medication) Sales Price by Application (2021-2026) & (US$/unit) Table 223. China Anti-Obesity Drugs (Anti-obesity Medication) Sales Price by Application (2027-2032) & (US$/unit) Table 224. Asia Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type (2021-2026) & (US$ Million) Table 225. Asia Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type (2027-2032) & (US$ Million) Table 226. Asia Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2021-2026) & (k units) Table 227. Asia Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2027-2032) & (k units) Table 228. Asia Anti-Obesity Drugs (Anti-obesity Medication) Sales Price by Type (2021-2026) & (US$/unit) Table 229. Asia Anti-Obesity Drugs (Anti-obesity Medication) Sales Price by Type (2027-2032) & (US$/unit) Table 230. Asia Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Application (2021-2026) & (US$ Million) Table 231. Asia Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Application (2027-2032) & (US$ Million) Table 232. Asia Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2021-2026) & (k units) Table 233. Asia Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2027-2032) & (k units) Table 234. Asia Anti-Obesity Drugs (Anti-obesity Medication) Sales Price by Application (2021-2026) & (US$/unit) Table 235. Asia Anti-Obesity Drugs (Anti-obesity Medication) Sales Price by Application (2027-2032) & (US$/unit) Table 236. Asia Anti-Obesity Drugs (Anti-obesity Medication) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 237. Asia Anti-Obesity Drugs (Anti-obesity Medication) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 238. Asia Anti-Obesity Drugs (Anti-obesity Medication) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 239. Asia Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 240. Asia Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2021-2026) & (k units) Table 241. Asia Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2027-2032) & (k units) Table 242. Asia Anti-Obesity Drugs (Anti-obesity Medication) Sales Price by Country (2021-2026) & (US$/unit) Table 243. Asia Anti-Obesity Drugs (Anti-obesity Medication) Sales Price by Country (2027-2032) & (US$/unit) Table 244. Japan Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2021-2032) & (US$ Million) Table 245. South Korea Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2021-2032) & (US$ Million) Table 246. India Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2021-2032) & (US$ Million) Table 247. Australia Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2021-2032) & (US$ Million) Table 248. Taiwan Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2021-2032) & (US$ Million) Table 249. Southeast Asia Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2021-2032) & (US$ Million) Table 250. SAMEA Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type (2021-2026) & (US$ Million) Table 251. SAMEA Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type (2027-2032) & (US$ Million) Table 252. SAMEA Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2021-2026) & (k units) Table 253. SAMEA Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2027-2032) & (k units) Table 254. SAMEA Anti-Obesity Drugs (Anti-obesity Medication) Sales Price by Type (2021-2026) & (US$/unit) Table 255. SAMEA Anti-Obesity Drugs (Anti-obesity Medication) Sales Price by Type (2027-2032) & (US$/unit) Table 256. SAMEA Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Application (2021-2026) & (US$ Million) Table 257. SAMEA Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Application (2027-2032) & (US$ Million) Table 258. SAMEA Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2021-2026) & (k units) Table 259. SAMEA Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2027-2032) & (k units) Table 260. SAMEA Anti-Obesity Drugs (Anti-obesity Medication) Sales Price by Application (2021-2026) & (US$/unit) Table 261. SAMEA Anti-Obesity Drugs (Anti-obesity Medication) Sales Price by Application (2027-2032) & (US$/unit) Table 262. SAMEA Anti-Obesity Drugs (Anti-obesity Medication) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 263. SAMEA Anti-Obesity Drugs (Anti-obesity Medication) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 264. SAMEA Anti-Obesity Drugs (Anti-obesity Medication) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 265. SAMEA Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 266. SAMEA Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2021-2026) & (k units) Table 267. SAMEA Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2027-2032) & (k units) Table 268. SAMEA Anti-Obesity Drugs (Anti-obesity Medication) Sales Price by Country (2021-2026) & (US$/unit) Table 269. SAMEA Anti-Obesity Drugs (Anti-obesity Medication) Sales Price by Country (2027-2032) & (US$/unit) Table 270. Brazil Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2021-2032) & (US$ Million) Table 271. Argentina Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2021-2032) & (US$ Million) Table 272. Chile Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2021-2032) & (US$ Million) Table 273. Colombia Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2021-2032) & (US$ Million) Table 274. Peru Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2021-2032) & (US$ Million) Table 275. Saudi Arabia Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2021-2032) & (US$ Million) Table 276. Israel Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2021-2032) & (US$ Million) Table 277. UAE Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2021-2032) & (US$ Million) Table 278. Turkey Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2021-2032) & (US$ Million) Table 279. Iran Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2021-2032) & (US$ Million) Table 280. Egypt Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2021-2032) & (US$ Million) Table 281. Key Raw Materials Table 282. Raw Materials Key Suppliers Table 283. Anti-Obesity Drugs (Anti-obesity Medication) Distributors List Table 284. Anti-Obesity Drugs (Anti-obesity Medication) Customers List Table 285. Research Programs/Design for This Report Table 286. Authors List of This Report Table 287. Secondary Sources Table 288. Primary Sources List of Figures Figure 1. Anti-Obesity Drugs (Anti-obesity Medication) Image Figure 2. Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size Share 2021 VS 2025 VS 2032 Figure 4. Rx Drug Image Figure 5. OTC Drug Image Figure 6. Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size Share 2021 VS 2025 VS 2032 Figure 8. Middle Aged (41-60) Image Figure 9. Juvenile (7-17) Image Figure 10. Youth (18-40) Image Figure 11. Elderly (Above 60) Image Figure 12. Childhood (0-6) Image Figure 13. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2021-2032) & (US$ Million) Figure 15. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 16. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Region: 2025 Versus 2032 Figure 17. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Region (2021-2032) Figure 18. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales (2021-2032) & (k units) Figure 19. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 20. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Region (2021-2032) Figure 21. US & Canada & Mexico Anti-Obesity Drugs (Anti-obesity Medication) Sales YoY (2021-2032) & (k units) Figure 22. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales YoY (2021-2032) & (k units) Figure 23. China Anti-Obesity Drugs (Anti-obesity Medication) Sales YoY (2021-2032) & (k units) Figure 24. Asia (Excluding China) Anti-Obesity Drugs (Anti-obesity Medication) Sales YoY (2021-2032) & (k units) Figure 25. South America, Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales YoY (2021-2032) & (k units) Figure 26. Global Anti-Obesity Drugs (Anti-obesity Medication) Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 27. Global Anti-Obesity Drugs (Anti-obesity Medication) Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 28. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Type (2021-2032) Figure 32. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 33. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Type (2021-2032) Figure 35. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 36. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Application (2021-2032) Figure 38. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 39. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Application (2021-2032) Figure 41. North America Anti-Obesity Drugs (Anti-obesity Medication) Revenue Share by Type (2021-2032) Figure 42. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales Share by Type (2021-2032) Figure 43. North America Anti-Obesity Drugs (Anti-obesity Medication) Revenue Share by Application (2021-2032) Figure 44. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales Share by Application (2021-2032) Figure 45. North America Anti-Obesity Drugs (Anti-obesity Medication) Revenue Share by Country (2021-2032) Figure 46. North America Anti-Obesity Drugs (Anti-obesity Medication) Sale

Scope & coverage.

Types
  • Rx Drug
  • OTC Drug
Applications
  • Middle Aged (41-60)
  • Juvenile (7-17)
  • Youth (18-40)
  • Elderly (Above 60)
  • Childhood (0-6)
Companies covered
  • Eisai
  • Sanofi
  • Novo Nordisk
  • Merck
  • F.Hoffmann-La Roche
  • Pfizer
  • GlaxoSmithKline
  • Bayer AG
  • AstraZeneca
  • Zafgan
  • Vivus
  • Shionogi
  • Rhythm Pharmaceuticals
  • Orexigen Therapeutics
  • Norgine
  • Boehringer Ingelheim
  • Arena Pharmaceuticals
  • Amylin
  • Alizyme
  • Alizyme

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Anti-Obesity Drugs (Anti-obesity Medication) Market by Type
  3. 1.2.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Rx Drug
  5. 1.2.3 OTC Drug
  6. 1.3 Anti-Obesity Drugs (Anti-obesity Medication) Market by Application
  7. 1.3.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Middle Aged (41-60)
  9. 1.3.3 Juvenile (7-17)
  10. 1.3.4 Youth (18-40)
  11. 1.3.5 Elderly (Above 60)
  12. 1.3.6 Childhood (0-6)
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Anti-Obesity Drugs (Anti-obesity Medication) Market Dynamics
  1. 2.1 Anti-Obesity Drugs (Anti-obesity Medication) Industry Trends
  2. 2.2 Anti-Obesity Drugs (Anti-obesity Medication) Industry Drivers
  3. 2.3 Anti-Obesity Drugs (Anti-obesity Medication) Industry Opportunities and Challenges
  4. 2.4 Anti-Obesity Drugs (Anti-obesity Medication) Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Region
  3. 3.2.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Region (2021-2026)
  5. 3.2.3 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Region (2027-2032)
  6. 3.2.4 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Region
  9. 3.4.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Region (2021-2026)
  11. 3.4.3 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Region (2027-2032)
  12. 3.4.4 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Manufacturers
  2. 4.1.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Anti-Obesity Drugs (Anti-obesity Medication) Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Manufacturers
  6. 4.2.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Anti-Obesity Drugs (Anti-obesity Medication) Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Anti-Obesity Drugs (Anti-obesity Medication) Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Anti-Obesity Drugs (Anti-obesity Medication) Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Anti-Obesity Drugs (Anti-obesity Medication) Manufacturers, Product Type & Application
  13. 4.7 Global Anti-Obesity Drugs (Anti-obesity Medication) Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Market CR5 and HHI
  16. 4.8.2 2025 Anti-Obesity Drugs (Anti-obesity Medication) Tier 1, Tier 2, and Tier 3
5 Anti-Obesity Drugs (Anti-obesity Medication) Market by Type
  1. 5.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type
  2. 5.1.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type
  6. 5.2.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2021-2032) & (k units)
  8. 5.2.3 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Type (2021-2032)
  9. 5.3 Global Anti-Obesity Drugs (Anti-obesity Medication) Price by Type
6 Anti-Obesity Drugs (Anti-obesity Medication) Market by Application
  1. 6.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Application
  2. 6.1.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application
  6. 6.2.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2021-2032) & (k units)
  8. 6.2.3 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Application (2021-2032)
  9. 6.3 Global Anti-Obesity Drugs (Anti-obesity Medication) Price by Application
7 Company Profiles
  1. 7.1 Eisai
  2. 7.1.1 Eisai Company Information
  3. 7.1.2 Eisai Business Overview
  4. 7.1.3 Eisai Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Eisai Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  6. 7.1.5 Eisai Recent Developments
  7. 7.2 Sanofi
  8. 7.2.1 Sanofi Company Information
  9. 7.2.2 Sanofi Business Overview
  10. 7.2.3 Sanofi Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Sanofi Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  12. 7.2.5 Sanofi Recent Developments
  13. 7.3 Novo Nordisk
  14. 7.3.1 Novo Nordisk Company Information
  15. 7.3.2 Novo Nordisk Business Overview
  16. 7.3.3 Novo Nordisk Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Novo Nordisk Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  18. 7.3.5 Novo Nordisk Recent Developments
  19. 7.4 Merck
  20. 7.4.1 Merck Company Information
  21. 7.4.2 Merck Business Overview
  22. 7.4.3 Merck Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Merck Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  24. 7.4.5 Merck Recent Developments
  25. 7.5 F.Hoffmann-La Roche
  26. 7.5.1 F.Hoffmann-La Roche Company Information
  27. 7.5.2 F.Hoffmann-La Roche Business Overview
  28. 7.5.3 F.Hoffmann-La Roche Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 F.Hoffmann-La Roche Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  30. 7.5.5 F.Hoffmann-La Roche Recent Developments
  31. 7.6 Pfizer
  32. 7.6.1 Pfizer Company Information
  33. 7.6.2 Pfizer Business Overview
  34. 7.6.3 Pfizer Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Pfizer Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  36. 7.6.5 Pfizer Recent Developments
  37. 7.7 GlaxoSmithKline
  38. 7.7.1 GlaxoSmithKline Company Information
  39. 7.7.2 GlaxoSmithKline Business Overview
  40. 7.7.3 GlaxoSmithKline Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 GlaxoSmithKline Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  42. 7.7.5 GlaxoSmithKline Recent Developments
  43. 7.8 Bayer AG
  44. 7.8.1 Bayer AG Company Information
  45. 7.8.2 Bayer AG Business Overview
  46. 7.8.3 Bayer AG Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Bayer AG Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  48. 7.8.5 Bayer AG Recent Developments
  49. 7.9 AstraZeneca
  50. 7.9.1 AstraZeneca Company Information
  51. 7.9.2 AstraZeneca Business Overview
  52. 7.9.3 AstraZeneca Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 AstraZeneca Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  54. 7.9.5 AstraZeneca Recent Developments
  55. 7.10 Zafgan
  56. 7.10.1 Zafgan Company Information
  57. 7.10.2 Zafgan Business Overview
  58. 7.10.3 Zafgan Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Zafgan Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  60. 7.10.5 Zafgan Recent Developments
  61. 7.11 Vivus
  62. 7.11.1 Vivus Company Information
  63. 7.11.2 Vivus Business Overview
  64. 7.11.3 Vivus Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Vivus Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  66. 7.11.5 Vivus Recent Developments
  67. 7.12 Shionogi
  68. 7.12.1 Shionogi Company Information
  69. 7.12.2 Shionogi Business Overview
  70. 7.12.3 Shionogi Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Shionogi Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  72. 7.12.5 Shionogi Recent Developments
  73. 7.13 Rhythm Pharmaceuticals
  74. 7.13.1 Rhythm Pharmaceuticals Company Information
  75. 7.13.2 Rhythm Pharmaceuticals Business Overview
  76. 7.13.3 Rhythm Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Rhythm Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  78. 7.13.5 Rhythm Pharmaceuticals Recent Developments
  79. 7.14 Orexigen Therapeutics
  80. 7.14.1 Orexigen Therapeutics Company Information
  81. 7.14.2 Orexigen Therapeutics Business Overview
  82. 7.14.3 Orexigen Therapeutics Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Orexigen Therapeutics Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  84. 7.14.5 Orexigen Therapeutics Recent Developments
  85. 7.15 Norgine
  86. 7.15.1 Norgine Company Information
  87. 7.15.2 Norgine Business Overview
  88. 7.15.3 Norgine Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Norgine Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  90. 7.15.5 Norgine Recent Developments
  91. 7.16 Boehringer Ingelheim
  92. 7.16.1 Boehringer Ingelheim Company Information
  93. 7.16.2 Boehringer Ingelheim Business Overview
  94. 7.16.3 Boehringer Ingelheim Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Boehringer Ingelheim Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  96. 7.16.5 Boehringer Ingelheim Recent Developments
  97. 7.17 Arena Pharmaceuticals
  98. 7.17.1 Arena Pharmaceuticals Company Information
  99. 7.17.2 Arena Pharmaceuticals Business Overview
  100. 7.17.3 Arena Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 Arena Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  102. 7.17.5 Arena Pharmaceuticals Recent Developments
  103. 7.18 Amylin
  104. 7.18.1 Amylin Company Information
  105. 7.18.2 Amylin Business Overview
  106. 7.18.3 Amylin Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 Amylin Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  108. 7.18.5 Amylin Recent Developments
  109. 7.19 Alizyme
  110. 7.19.1 Alizyme Company Information
  111. 7.19.2 Alizyme Business Overview
  112. 7.19.3 Alizyme Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue, Price and Gross Margin (2021-2026)
  113. 7.19.4 Alizyme Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  114. 7.19.5 Alizyme Recent Developments
  115. 7.20 Alizyme
  116. 7.20.1 Alizyme Company Information
  117. 7.20.2 Alizyme Business Overview
  118. 7.20.3 Alizyme Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue, Price and Gross Margin (2021-2026)
  119. 7.20.4 Alizyme Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  120. 7.20.5 Alizyme Recent Developments
8 North America
  1. 8.1 North America Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Type
  2. 8.1.1 North America Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type (2021-2032)
  3. 8.1.2 North America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2021-2032)
  4. 8.1.3 North America Anti-Obesity Drugs (Anti-obesity Medication) Price by Type (2021-2032)
  5. 8.2 North America Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Application
  6. 8.2.1 North America Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Application (2021-2032)
  7. 8.2.2 North America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2021-2032)
  8. 8.2.3 North America Anti-Obesity Drugs (Anti-obesity Medication) Price by Application (2021-2032)
  9. 8.3 North America Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Country
  10. 8.3.1 North America Anti-Obesity Drugs (Anti-obesity Medication) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Anti-Obesity Drugs (Anti-obesity Medication) Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Type
  2. 9.1.1 Europe Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type (2021-2032)
  3. 9.1.2 Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2021-2032)
  4. 9.1.3 Europe Anti-Obesity Drugs (Anti-obesity Medication) Price by Type (2021-2032)
  5. 9.2 Europe Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Application
  6. 9.2.1 Europe Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Application (2021-2032)
  7. 9.2.2 Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2021-2032)
  8. 9.2.3 Europe Anti-Obesity Drugs (Anti-obesity Medication) Price by Application (2021-2032)
  9. 9.3 Europe Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Country
  10. 9.3.1 Europe Anti-Obesity Drugs (Anti-obesity Medication) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Anti-Obesity Drugs (Anti-obesity Medication) Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Type
  2. 10.1.1 China Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type (2021-2032)
  3. 10.1.2 China Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2021-2032)
  4. 10.1.3 China Anti-Obesity Drugs (Anti-obesity Medication) Price by Type (2021-2032)
  5. 10.2 China Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Application
  6. 10.2.1 China Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Application (2021-2032)
  7. 10.2.2 China Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2021-2032)
  8. 10.2.3 China Anti-Obesity Drugs (Anti-obesity Medication) Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Type
  2. 11.1.1 Asia Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type (2021-2032)
  3. 11.1.2 Asia Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2021-2032)
  4. 11.1.3 Asia Anti-Obesity Drugs (Anti-obesity Medication) Price by Type (2021-2032)
  5. 11.2 Asia Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Application
  6. 11.2.1 Asia Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Application (2021-2032)
  7. 11.2.2 Asia Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2021-2032)
  8. 11.2.3 Asia Anti-Obesity Drugs (Anti-obesity Medication) Price by Application (2021-2032)
  9. 11.3 Asia Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Country
  10. 11.3.1 Asia Anti-Obesity Drugs (Anti-obesity Medication) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Anti-Obesity Drugs (Anti-obesity Medication) Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Type
  2. 12.1.1 SAMEA Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Anti-Obesity Drugs (Anti-obesity Medication) Price by Type (2021-2032)
  5. 12.2 SAMEA Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Application
  6. 12.2.1 SAMEA Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Anti-Obesity Drugs (Anti-obesity Medication) Price by Application (2021-2032)
  9. 12.3 SAMEA Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Country
  10. 12.3.1 SAMEA Anti-Obesity Drugs (Anti-obesity Medication) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Anti-Obesity Drugs (Anti-obesity Medication) Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Anti-Obesity Drugs (Anti-obesity Medication) Value Chain Analysis
  2. 13.1.1 Anti-Obesity Drugs (Anti-obesity Medication) Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Anti-Obesity Drugs (Anti-obesity Medication) Production Mode & Process
  6. 13.2 Anti-Obesity Drugs (Anti-obesity Medication) Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Anti-Obesity Drugs (Anti-obesity Medication) Distributors
  9. 13.2.3 Anti-Obesity Drugs (Anti-obesity Medication) Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst